Monoclonal Protein Study, Expanded Panel, Serum
Also known as: IFE FLC
Use
Aids in the diagnosis and monitoring of monoclonal gammopathies. This panel includes serum free light chain testing, eliminating the need for urine monoclonal studies as part of initial screening. It is used to detect, quantify, and characterize serum monoclonal protein, which is crucial for managing conditions such as multiple myeloma and other related plasma cell disorders.
Special Instructions
A copy of the graph follows the final report. This assay is highly sensitive to increasing concentrations of monoclonal free kappa or lambda light chains in patients with evolving or relapsing myelomas.
Limitations
Undetected antigen excess is a rare event but cannot be excluded. Free light chain results should always be interpreted in conjunction with other clinical and laboratory findings. Results should not be used as the sole criteria for diagnosis, and clinical correlation is required.
FDA ApprovedNew York Approved
Methodology
Immunoassay (Multiplex Protein Panel)
Biomarkers
LOINC Codes
- 2862-1
- 2865-4
- 2868-8
- 2871-2
- 2874-6
- 25700-6
- 2458-8
- 2465-3
- 2472-9
- 2885-2
- 36916-5
- 33944-0
- 80517-6
- 49275-1
- 33358-3
- 11502-2
Result Turnaround Time
1-5 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
2.5 mL
Minimum Volume
2.0 mL
Container
Serum separator tube (SST)
Collection Instructions
Separate from cells ASAP or within 2 hours of collection and transfer to an ARUP standard transport tube.
Causes for Rejection
Plasma; Room temperature specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | Unacceptable |
| Refrigerated | 1 week |
| Frozen | 1 month |